Shanghai No.1 Pharmacy Co.,Ltd. (SHA:600833)
China
· Delayed Price · Currency is CNY 11.85
+0.28 (2.42%)
Apr 29, 2026, 3:00 PM CST
Shanghai No.1 Pharmacy Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,070 | 1,864 | 1,767 | 2,617 | 1,342 | Upgrade
|
| Other Revenue | 59.74 | 51.35 | 52.23 | 38.5 | 56.25 | Upgrade
|
| Revenue | 2,130 | 1,915 | 1,820 | 2,656 | 1,398 | Upgrade
|
| Revenue Growth (YoY) | 11.23% | 5.26% | -31.49% | 89.94% | -11.89% | Upgrade
|
| Cost of Revenue | 1,790 | 1,598 | 1,474 | 2,116 | 1,153 | Upgrade
|
| Gross Profit | 340.08 | 317.2 | 345.21 | 540.36 | 244.86 | Upgrade
|
| Selling, General & Admin | 339.61 | 318.56 | 315.85 | 307.58 | 230.69 | Upgrade
|
| Other Operating Expenses | 5.96 | 5.88 | 8.36 | 9.53 | 4.71 | Upgrade
|
| Operating Expenses | 346.04 | 305.27 | 333.8 | 333.73 | 235.93 | Upgrade
|
| Operating Income | -5.97 | 11.93 | 11.41 | 206.63 | 8.94 | Upgrade
|
| Interest Expense | -4.51 | -6.05 | -7.59 | -14.12 | -3.15 | Upgrade
|
| Interest & Investment Income | 25.09 | 33.86 | 25.31 | 17.89 | 24.23 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.59 | -0.18 | 0.19 | 0.05 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.8 | 3.42 | -3.4 | -3.94 | 0.26 | Upgrade
|
| EBT Excluding Unusual Items | 12.22 | 42.98 | 25.92 | 206.51 | 30.27 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | 0.38 | 12.14 | 0.29 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 49.84 | 168.89 | 64.73 | -0.07 | 1.23 | Upgrade
|
| Asset Writedown | -1.3 | -4.99 | -4.69 | -19.99 | - | Upgrade
|
| Other Unusual Items | 15.3 | 9.02 | 19.41 | 3.79 | 33.75 | Upgrade
|
| Pretax Income | 76.05 | 216.27 | 117.51 | 190.52 | 65.24 | Upgrade
|
| Income Tax Expense | 17.51 | 52.66 | 28.24 | 46.96 | 15.82 | Upgrade
|
| Earnings From Continuing Operations | 58.54 | 163.62 | 89.28 | 143.56 | 49.42 | Upgrade
|
| Minority Interest in Earnings | -0.79 | -0.55 | - | - | - | Upgrade
|
| Net Income | 57.75 | 163.06 | 89.28 | 143.56 | 49.42 | Upgrade
|
| Net Income to Common | 57.75 | 163.06 | 89.28 | 143.56 | 49.42 | Upgrade
|
| Net Income Growth | -64.59% | 82.65% | -37.81% | 190.49% | -27.90% | Upgrade
|
| Shares Outstanding (Basic) | 222 | 223 | 223 | 224 | 225 | Upgrade
|
| Shares Outstanding (Diluted) | 222 | 223 | 223 | 224 | 225 | Upgrade
|
| Shares Change (YoY) | -0.57% | 0.08% | -0.50% | -0.14% | 1.60% | Upgrade
|
| EPS (Basic) | 0.26 | 0.73 | 0.40 | 0.64 | 0.22 | Upgrade
|
| EPS (Diluted) | 0.26 | 0.73 | 0.40 | 0.64 | 0.22 | Upgrade
|
| EPS Growth | -64.38% | 82.50% | -37.50% | 190.91% | -29.03% | Upgrade
|
| Free Cash Flow | 72.95 | -2.91 | 44.61 | 120.94 | 23.92 | Upgrade
|
| Free Cash Flow Per Share | 0.33 | -0.01 | 0.20 | 0.54 | 0.11 | Upgrade
|
| Dividend Per Share | 0.078 | 0.220 | 0.125 | 0.195 | 0.070 | Upgrade
|
| Dividend Growth | -64.55% | 76.00% | -35.90% | 178.57% | -26.32% | Upgrade
|
| Gross Margin | 15.96% | 16.56% | 18.97% | 20.34% | 17.51% | Upgrade
|
| Operating Margin | -0.28% | 0.62% | 0.63% | 7.78% | 0.64% | Upgrade
|
| Profit Margin | 2.71% | 8.51% | 4.91% | 5.41% | 3.53% | Upgrade
|
| Free Cash Flow Margin | 3.43% | -0.15% | 2.45% | 4.55% | 1.71% | Upgrade
|
| EBITDA | 1.3 | 19.43 | 18.79 | 214.25 | 16.71 | Upgrade
|
| EBITDA Margin | 0.06% | 1.01% | 1.03% | 8.07% | 1.20% | Upgrade
|
| D&A For EBITDA | 7.26 | 7.51 | 7.38 | 7.62 | 7.77 | Upgrade
|
| EBIT | -5.97 | 11.93 | 11.41 | 206.63 | 8.94 | Upgrade
|
| EBIT Margin | -0.28% | 0.62% | 0.63% | 7.78% | 0.64% | Upgrade
|
| Effective Tax Rate | 23.03% | 24.35% | 24.03% | 24.65% | 24.25% | Upgrade
|
| Revenue as Reported | 2,130 | 1,915 | 1,820 | 2,656 | 1,398 | Upgrade
|
| Advertising Expenses | 5.08 | 6.11 | 6.6 | 4.75 | 2.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.